Interest of liposomal doxorubicin as a radiosensitizer in malignant glioma xenografts

EA 4001 Radiopotentialisation: de la préclinique à la clinique, Faculté de Médecine, Nancy Université, 9 avenue de la Forêt de Haye-BP 184, Vandoeuvre-les-Nancy, Nancy, France.
Anti-Cancer Drugs (Impact Factor: 1.78). 12/2008; 19(10):991-8. DOI: 10.1097/CAD.0b013e328313e172
Source: PubMed

ABSTRACT Malignant glioma patients have a life expectancy reduced to about 15 months despite aggressive surgery, radiotherapy (RT), and chemotherapy. Doxorubicin has shown a marked cytotoxic effect against malignant glioma cells in vitro. The brain exposure to this drug is, however, hindered by the blood-brain barrier. Encapsulation of doxorubicin in liposomal carriers has been shown to reduce toxicities and to improve brain tumors exposure to doxorubicin. In this study, we evaluated the radiosensitizing properties of a nonpegylated liposomal doxorubicin (Myocet, MYO) on two subcutaneous (U87 and TCG4) and one intracranial (U87) malignant glioma models xenografted on nude mice. Doxorubicin biodistribution was assessed by a high-performance liquid chromatography method. Antitumor efficacy was investigated by tumor volume measurements and mice survival determination. We showed that (i) encapsulation of doxorubicin ensured a preferential deposition of doxorubicin in tumoral tissue in comparison with free doxorubicin; (ii) doxorubicin accumulated in both subcutaneous and intracranial tumors during repeated injections of MYO and this accumulation was linked to the potentiation of RT efficacy on two subcutaneous models; (iii) MYO was unable to improve the antitumoral efficacy of RT on an intracranial glioma model. Finally, this study emphasizes the importance of performing preclinical studies on models closer as possible of human tumors and localization to be more predictive of therapeutic effects observed in humans.

16 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: This work was conducted to evaluate the potential antitumor effect of an in vivo plasma treatment on a U87-luc glioma tumor. A pulsed DBD with mu s pulses at moderate power was used for treatment. Electrical analyses and spectroscopic measurements were realized to characterize plasma properties. We showed that the plasma treatment was safe for mice. However, the reiterated long time plasma treatment (20 mm, 3 consecutive days) produces a superficial burn. During plasma treatment, we observed an increase of subcutaneous temperature and a cutaneous skin pH reduction. After 5 d of plasma treatment, we observed a dramatical U87 bioluminescence decrease associated with a reduction of tumor volume in U87 glioma-bearing mice.
    Plasma Processes and Polymers 03/2010; 7(3-3-4):264-273. DOI:10.1002/ppap.200900080 · 2.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Local recurrence of feline soft tissue sarcomas is common despite aggressive treatment. Liposomal doxorubicin might serve as a depot radiosensitizer if administered concomitantly with daily radiotherapy and thus improve tumor control. In this pilot study, the feasibility of concomitant liposomal radiochemotherapy was evaluated in a palliative setting in 10 cats with advanced soft tissue sarcomas. Cats were treated with median number of 5 (range 5-7) daily fractions of radiotherapy and a median total dose of 20 Gy (range 20-31.5 Gy). One dose of liposomal doxorubicin was administered at the beginning of radiotherapy. Seven cats received further free or liposomal doxorubicin after completion of the liposomal doxorubicin/radiation protocol. Seven of the treated 10 cats (70%) achieved a partial (n=5) or complete (n=2) response with a median response duration of 237 days. The median progression free interval in all 10 cats was 117 days and the median overall survival time was 324 days. Concomitant liposomal radiochemotherapy was tolerated well in nine cats, one cat experienced temporary anorexia. Although the number of patients is too small to make definitive conclusions, results appear promising enough to investigate the role of liposomal doxorubicin as a radiosensitizer further.
    Veterinary Radiology &amp Ultrasound 05/2010; 51(3):349-55. DOI:10.1111/j.1740-8261.2009.01661.x · 1.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Non thermal atmospheric plasma is a new promising candidate in anticancer therapy. We have already reported the absence of skin damage induced by our plasma treatment. Preliminary results suggested that this treatment could also induce an antitumor effect on U87 malignant glioma xenografts, and we conducted this work to evaluate the antitumor efficacy of plasma in this model. Antitumor effects were assessed by tumor volume measurement and bioluminescence imaging (BLI). Plasma treatment was applied during five consecutive days in open air with a μs-duration pulsed floating electrode dielectric barrier discharge (FE-DBD), which delivered about 0.75 W at 200 Hz on the mouse skin. Our results showed a significant tumor volume decrease of 56% for treated mice at the end of the treatment, with a concomitant decrease of BLI intensity. Moreover, this tumor volume reduction translated into an increase of mouse life span of 60%, median survival being 9.5 and 15.0 days for control and plasma-treated mice, respectively. In conclusion, our study demonstrates a marked antitumor effect of plasma treatment in U87 glioma xenografts. These results, obtained in both a radio and chemoresistant model, are very promising and highlight the potential of plasma treatment as an anticancer treatment with little or no toxic side effects.
    Plasma Medicine 01/2011; 1(1-1):27-43. DOI:10.1615/PlasmaMed.v1.i1.30
Show more